Navigation Links
Asmacure Ltee to Present at the 2011 BioPharm America Conference
Date:9/1/2011

QUEBEC CITY, Sept. 1, 2011 /PRNewswire/ -- Asmacure Ltee, a clinical-stage biopharmaceutical company focused on the development of nicotinic receptor agonists for the treatment of asthma and other inflammatory diseases, announced today that CEO Martin Driscoll will present at the 2011 BioPharm America Conference taking place September 7-9.  Mr. Driscoll will provide an overview of Asmacure's nicotinic acetylcholine receptor technology, with emphasis on the company's lead product in development for the treatment of asthma, ASM-024.  The presentation will be given on Friday, September 9, at 9:00 a.m. EDT in the Hancock room at the Westin Boston Waterfront Hotel in Boston, MA.

About Asmacure Ltee

Asmacure Ltee is a clinical-stage biopharmaceutical company focused on the development of nicotinic receptor agonists for the treatment of asthma and other inflammatory diseases.  The company's lead compound, ASM-024, is a novel molecular entity currently in clinical development for the treatment of asthma.  ASM-024 utilizes Asmacure's proprietary technology comprised of nicotinic acetylcholine receptor agonists and is the first nicotinic receptor agonist in the clinic for this indication.  Phase II proof-of-concept studies are ongoing to assess the anti-inflammatory, bronchodilating and bronchoprotective properties of ASM-024 administered by inhalation.  

Asmacure is a privately held company located in Quebec City, Canada.  The major investors in Asmacure include Domain Associates, Fonds Bio-Innovation and Innovatech Quebec.  For more information visit www.asmacure.com

Media Contacts:
Tiberend Strategic Advisors, Inc.
(212) 827-0020
Andrew Mielach, amielach@tiberend.com
or
Claire Sojda, csojda@tiberend.com  


'/>"/>
SOURCE Asmacure Ltee
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Asmacure Ltee Appoints Pharmaceutical and Biotechnology Industry Veteran Martin Driscoll as CEO
2. Verenium to Present at Upcoming Conferences
3. Idenix Pharmaceuticals to Present at Three Upcoming Investor Conferences
4. Hadasit to Present at the Rodman & Renshaw Annual Global Investment Conference on September 13, 2011
5. Auxilium Pharmaceuticals to Present at the Morgan Stanley 2011 Healthcare Conference
6. PAREXEL International to Present at Robert Baird Healthcare Conference and William Blair Emerging Growth Stock Conference
7. Life Technologies to Present at the UBS 2011 Global Life Sciences Conference
8. Questcor Pharmaceuticals to Present at Upcoming Investor Conferences in September
9. Bacterin International to Present at Stifel Nicolaus 2011 Healthcare Conference on September 8, 2011
10. Amgen Highlights Data to Be Presented at American Society for Bone and Mineral Research Meeting
11. Insmed to Present at 2011 Wedbush Securities Life Sciences Management Access Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... , ... October 11, 2017 , ... ... gene in its endogenous context, enabling overexpression experiments and avoiding the use of ... small RNA guides is transformative for performing systematic gain-of-function studies. , This ...
(Date:10/11/2017)... INDIANAPOLIS , Oct. 11, 2017  VMS BioMarketing, a ... of a nationwide oncology Clinical Nurse Educator (CNE) network, which ... growing need for communication among health care professionals to enhance ... physicians, nurses, office staff, and other health care professionals to ... for breast cancer. ...
(Date:10/11/2017)... , ... October 11, 2017 , ... ... (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer ... treatment of osteosarcoma. SBT-100 is able to cross the cell membrane and bind ...
(Date:10/10/2017)... ... October 10, 2017 , ... Dr. Bob Harman, founder and CEO of ... Club. The event entitled “Stem Cells and Their Regenerative Powers,” was ... Dr. Harman, DVM, MPVM was joined by two human doctors: Peter B. Hanson, M.D., ...
Breaking Biology Technology:
(Date:10/4/2017)... 2017  GCE Solutions, a global clinical research organization (CRO), announces ... solution on October 4, 2017. Shadow is designed to assist medical ... policy 0070 of the European Medicines Agency (EMA) in meeting the ... ... ...
(Date:7/20/2017)... , July 20, 2017 Delta (NYSE: DAL ) ... any Delta aircraft at Reagan Washington National Airport (DCA). ... Delta launches biometrics to board ... Delta,s biometric boarding ... Club is now integrated into the boarding process to allow eligible ...
(Date:6/14/2017)... (NYSE: IBM ) is introducing several innovative partner startups ... collaboration between startups and global businesses, taking place in ... nine startups will showcase the solutions they have built with ... France is one of the ... percent increase in the number of startups created between 2012 ...
Breaking Biology News(10 mins):